Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Subcutaneous amivantamab combinations in EGFR-mutated advanced or metastatic non-small cell lung cancer
ISRCTN12138139Phase 2Recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Dec 2024
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
01
Overview
Phase 2, open-label trial of amivantamab and lazertinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Progression Free Survival. Started Dec 2024; status: recruiting.
02
Drugs
amivantamablazertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ISRCTN12138139.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN12138139.